Patient outcomes
| Response . | All patients (N = 119) . | Spliceosome (n = 39) . | No spliceosome (n = 80) . | P . |
|---|---|---|---|---|
| ORR | 97 (81) | 34 (89) | 63 (79) | .32 |
| CRc | 91 (76) | 31 (79) | 60 (75) | .65 |
| CR | 71 (60) | 20 (51) | 51 (64) | .23 |
| CRi/CRh | 20 (17) | 11 (28) | 9 (11) | .03 |
| MLFS | 6 (5) | 3 (10) | 3 (4) | .39 |
| NR/died | 22 (18) | 5 (13) | 17 (21) | .32 |
| Composite CR by molecular group | P* | |||
| NPM1 (n = 29) | 27 (93) | 9/11 (82) | 18/18 (100) | .02 |
| IDH1 (n = 10) | 6 (60) | 3/5 (60) | 3/5 (60) | .24 |
| IDH2 (n = 16) | 14 (88) | 8/9 (89) | 6/7 (86) | .35 |
| FLT3-ITD/TKD (n = 20) | 16 (80) | 4/5 (80) | 12/15 (80) | .78 |
| TP53 (n = 36) | 21 (58) | 3/6 (50) | 18/30 (60) | .01 |
| Adverse/complex cytogenetics (n = 50) | 32 (64) | 5/11 (45) | 27/39 (69) | .01 |
| Response . | All patients (N = 119) . | Spliceosome (n = 39) . | No spliceosome (n = 80) . | P . |
|---|---|---|---|---|
| ORR | 97 (81) | 34 (89) | 63 (79) | .32 |
| CRc | 91 (76) | 31 (79) | 60 (75) | .65 |
| CR | 71 (60) | 20 (51) | 51 (64) | .23 |
| CRi/CRh | 20 (17) | 11 (28) | 9 (11) | .03 |
| MLFS | 6 (5) | 3 (10) | 3 (4) | .39 |
| NR/died | 22 (18) | 5 (13) | 17 (21) | .32 |
| Composite CR by molecular group | P* | |||
| NPM1 (n = 29) | 27 (93) | 9/11 (82) | 18/18 (100) | .02 |
| IDH1 (n = 10) | 6 (60) | 3/5 (60) | 3/5 (60) | .24 |
| IDH2 (n = 16) | 14 (88) | 8/9 (89) | 6/7 (86) | .35 |
| FLT3-ITD/TKD (n = 20) | 16 (80) | 4/5 (80) | 12/15 (80) | .78 |
| TP53 (n = 36) | 21 (58) | 3/6 (50) | 18/30 (60) | .01 |
| Adverse/complex cytogenetics (n = 50) | 32 (64) | 5/11 (45) | 27/39 (69) | .01 |
Data are n (%) or n/N (%).
MLFS, morphologic leukemia-free state.
P value for all patients (spliceosome and wild-type) within a classified molecular group.